Inborn Errors of Metabolism That Cause Sudden Infant Death: A Systematic Review with Implications for Population Neonatal Screening Programmes

Willemijn J. van Rijt^a Geneviève D. Koolhaas^c Jolita Bekhof^c
M. Rebecca Heiner Fokkema^b Tom J. de Koning^a Gepke Visser^d
Peter C.J.I. Schielen^e Francjan J. van Spronsen^a Terry G.J. Derks^a

^aSection of Metabolic Diseases, Beatrix Children's Hospital, and ^bLaboratory of Metabolic Diseases, Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, ^cPrincess Amalia Children's Clinic, Isala Hospital, Zwolle, ^dDepartment of Metabolic Diseases, Wilhelmina Children's Hospital, UMCU, Utrecht, and ^eLaboratory of Infectious Diseases and Screening, National Institute of Public Health and Environment (RIVM), Bilthoven, The Netherlands

Key Words

Neonatal screening · Inborn error of metabolism · Mitochondrial fatty acid oxidation · Reye syndrome · Sudden infant death · Metabolic autopsy

Abstract

Background: Many inborn errors of metabolism (IEMs) may present as sudden infant death (SID). Nowadays, increasing numbers of patients with IEMs are identified pre-symptomatically by population neonatal bloodspot screening (NBS) programmes. However, some patients escape early detection because their symptoms and signs start before NBS test results become available, they even die even before the sample for NBS has been drawn or because there are IEMs which are not included in the NBS programmes. **Objectives and Methods:** This was a comprehensive systematic literature review to identify all IEMs associated with SID, including their treatability and detectability by NBS technologies. Reye syndrome (RS) was included in the search strategy because this

condition can be considered a possible pre-stage of SID in a continuum of aggravating symptoms. **Results:** 43 IEMs were identified that were associated with SID and/or RS. Of these, (1) 26 can already present during the neonatal period, (2) treatment is available for at least 32, and (3) 26 can currently be identified by the analysis of acylcarnitines and amino acids in dried bloodspots (DBS). **Conclusion:** We advocate an extensive analysis of amino acids and acylcarnitines in blood/plasma/DBS and urine for all children who died suddenly and/or unexpectedly, including neonates in whom blood had not yet been drawn for the routine NBS test. The application of combined metabolite screening and DNA-sequencing techniques would facilitate fast identification and maximal diagnostic yield. This is important information for clinicians who need to maintain clinical awareness and decision-makers to improve population NBS programmes.

© 2016 The Author(s)
Published by S. Karger AG, Basel

Willemijn J. van Rijt and Geneviève D. Koolhaas contributed equally to this work.

Introduction

Many inborn errors of metabolism (IEMs) that cause cellular energy deficiency and/or intoxication are associated with sudden infant death (SID). Based on retrospective studies, approximately 0.9–6% of all SID cases involve IEMs [1–3]. Although these studies were subject to several forms of selection bias, they formed the rationale behind metabolic autopsy protocols for young children, which include analyses of amino acid and acylcarnitine profiles in plasma/urine [4].

Since the 1990s, tandem mass spectrometry (TMS) of dried blood spots (DBS) has been developed to perform high-throughput simultaneous quantitative analysis of different diagnostic metabolites in small amounts in biological samples [5]. As a consequence, in the last 2 decades, population neonatal bloodspot screening (NBS) programmes have expanded to include many IEMs. Patients with treatable IEMs can remain undetected by population NBS programmes for several reasons. In some IEMs, symptoms and signs including death may already occur before the NBS test results become available or even before blood for testing has been drawn, annulling the benefits of NBS [6–10]. This is especially relevant in areas where neonatal blood is collected relatively late, for instance, in the Netherlands (i.e. 72–168 h after birth) [11, 12]. Worldwide, across different areas, population NBS programmes differ with respect to the methodological aspects and the disorders screened.

Systematic studies on the percentage of IEMs in SID cases are required because, although rare, SID that is preventable due to the IEM concerned being treatable does still occur. Therefore, we performed this comprehensive systematic literature review to identify IEMs that (1) are associated with SID, (2) have clinical ascertainment during the neonatal period, (3) are treatable and (4) are detectable on TMS.

Methods

Search Strategy

A literature search for relevant references was performed according to the Cochrane Collaboration methodology. The CINAHL, Cochrane, PubMed and Embase public databases were searched using both MeSH terms and free text. A detailed presentation and assessment of the search strategy, including the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 checklist, is presented in the online supplementary data (see www.karger.com/doi/10.1159/000443874 for all online suppl. material). Figure 1 presents the flow chart of the detailed search strategy together with the steps of the systematic review.

Fig. 1. Flow chart of detailed search strategy. CINAHL, Cochrane, PubMed and Embase were searched using both MeSH terms and free text: ‘Metabolism, Inborn Errors’ (MeSH) OR ‘inborn errors of metabolism’ OR ‘mitochondrial fatty acid oxidation’ AND ‘Sudden Infant Death’ (MeSH) OR ‘sudden infant death’ OR ‘sudden infant death syndrome’ OR ‘unexpected death’ OR ‘sudden unexpected death of infant’ OR ‘Reye syndrome’ (MeSH) AND ‘Humans’ (MeSH) AND ‘Infant, Newborn, Child, Adolescent’ (MeSH) OR ‘newborn’ OR ‘infant’ OR ‘child’. The search was conducted on 15 February 2013. Due to the time that elapsed between the execution of the search and the completion of the paper, the search was repeated on 28 August 2015 to screen for possible extra IEMs. This led to the inclusion of only 1 more IEM associated with either SIDS and/or RS: dihydrolipoamide dehydrogenase deficiency (DLD deficiency; MIM No. 246900).

The following search terms were included to further optimize our search. The term ‘mitochondrial fatty acid oxidation’ was included because, based on previous studies and our personal expertise, this disease group has the highest incidence of IEMs associated with both SID [1–3] and NBS programmes [6, 7, 10]. SID is historically defined as occurring in the first year of life. We therefore expanded our search strategy, adding the term ‘sudden unex-

pected death of infant'. Originally, Reye syndrome (RS) was described as a non-inflammatory encephalopathy in childhood, associated with hepatic dysfunction [13]. Since the 1980s, it has been recognized as a presenting symptom of IEMs rather than an etiologic diagnosis [14]. We considered RS as a potential pre-stage of SID in a continuum of aggravating symptoms. We therefore also included the term 'Reye syndrome' in our search.

All reports published since 1990 were included, corresponding with the first publications about the availability of TMS and the general progressions made with molecular and enzymatic confirmatory testing in the field of IEMs. References published before 1990 were only included when available upon request. Two independent reviewers (G.K. and T.D.) performed title and abstract screenings. Consensus about inclusion was reached during regular meetings. Subsequently, 3 independent reviewers (W.v.R., G.K. and T.D.) screened the full-text articles of all selected references. The inclusion of a diagnosis as a cause of SID and/or RS was based on the presence of detailed patient data and a confirmed diagnosis in the full-text articles. Specific exclusion criteria were: (1) no detailed patient data reported, (2) a lack of accessibility of the articles, (3) confirmatory metabolite, molecular or enzymatic studies were inconclusive, (4) there had been a (possible) additional contributing cause of death, (5) RS patients were >18 years old and (6) the abstract and/or article was not available in either English or Dutch.

Data Analysis

All IEMs were classified according to the Society for the Study of Inborn Errors of Metabolism classification of IEMs [15]. Based on the included references, associations between confirmed diagnoses and SID and/or RS were documented (e.g. table 1: '+' in the SID column indicates that the particular IEM has been associated with SID in at least 1 of the corresponding references in online suppl. table 1). Neonatal clinical presentation was reported based on detailed patient data from the included references. Based on recent textbooks and the literature, the treatability [16] and detectability by TMS of a DBS [17–19] were documented, respectively.

Results

This systematic review included a total of 136 references. Table 1 presents the 43 IEMs associated with either SID and/or RS, concerning mostly disorders of mitochondrial fatty acid oxidation, the urea cycle and organic acidurias. References of all included articles are presented in online supplementary table 1. Out of these 43 IEMs, 26 had presented already during the neonatal period, and 15 were found to be treatable and also detectable with TMS methodologies. In at least 32 of the IEMs, a specific dietary and/or pharmacological treatment is available in order to prevent clinical presentation. Identification by population NBS programmes by TMS analysis of amino acids and/or acylcarnitines in DBS is possible in 26 of the IEMs.

Discussion

This unique systematic literature review identified at least 43 IEMs associated with SID and/or RS, 26 of which can already present during the neonatal period. At least 32 are considered as treatable disorders and 26 are currently detectable by TMS analysis of amino acids and/or acylcarnitines in DBS. The remaining 17 cannot be detected by current metabolite screening methods but require additional testing either by expanding the metabolic testing options or by means of genetic and/or enzymatic laboratory methods. Out of the 26 IEMs in which feasibility of clinical ascertainment within the neonatal period has been reported, at least 15 are treatable and are detectable by TMS analysis. This is important information to for the improvement of population NBS programmes because early detection and subsequent appropriate treatment can prevent clinical presentation and even death (table 1). Moreover, considering the results of our study, we propose that diagnostic (laboratory) protocols can be improved for children (including neonates) presenting with sudden/unexpected death.

There is no doubt that the expanded population NBS programmes have significantly improved the outcomes of many patients, but there is still a subset of patients that unfortunately escapes early identification [20]. In one group, this is because limited numbers of IEMs are included in NBS programmes. It is important to realize that population NBS programmes vary worldwide, and maybe even within countries. In another group, it is because the symptoms and signs present before the NBS test results become available or even before blood has been drawn. This is aggravated by the relatively late drawing of blood and/or follow-up after positive test results in some areas/countries. In the Netherlands, the blood for the NBS test is collected between 72 and 168 h after birth [11, 12]. In 2013, the response rate for the NBS programme was 99.35%. Referral to a metabolic physician was initiated before day 8 in 62% of the positive neonates, but 441 out of 173,118 newborns died (etiology was not specified) before blood could be drawn [11]. The reports on population NBS programmes from Australia, the USA and Germany present patients with clinical ascertainment and sometimes even neonatal death before the NBS test results have become available (see: ^a in table 1) [6, 7, 10]. In line with these reports, since the expansion of the NBS programme in our country (table 1), clinical symptoms and signs have often preceded the NBS test results, sometimes even leading to early death, in cases of very long-chain acyl-CoA dehydrogenase deficiency, long-chain

Table 1. IEMs associated with SID and/or RS

Disorder	Neonatal presentation	RS	SID	Treatable	DBS	Phenotype MIM No.
<i>Amino acid and peptide metabolism</i>						
Urea cycle disorders						
Carbamoylphosphate synthetase I deficiency	+	+	+	+	+ ^d	237300
Ornithine transcarbamylase deficiency ^a	+	+	+	+	+ ^d	311250
Citrullinemia type I ^a	+	+	+	+	+ ^d	215700
Argininosuccinic aciduria	–	–	+	+	+ ^d	207900
Organic acidurias						
Glutaric aciduria type I ^{a, b}	–	–	+	+	+ ^d	231670
Propionic aciduria ^{a, c}	+	+	–	+	+ ^d	232000
Methylmalonic aciduria ^{a, c}	+	+	+	+	+ ^d	251000
Isovaleric aciduria ^{a, b}	–	–	+	+	+ ^d	243500
Methylglutaconic aciduria, type I	–	+	–	+	+ ^d	250950
Methylglutaconic aciduria, type II (Barth syndrome)	+	+	+	+	–	302060
3-Hydroxy-3-methylglutaric aciduria	+	+	–	+	+ ^d	246450
Alpha-methylacetoacetic aciduria ^c	–	+	–	+	+ ^d	203750
L-2-hydroxyglutaric aciduria	–	–	+	–	–	236792
Disorders of the metabolism of branched-chain amino acids not classified as organic acidurias						
Dihydrolipoamide dehydrogenase deficiency ¹	+	+	–	–	–	246900
Disorders of phenylalanine or tyrosine metabolism						
Tyrosinemia type I ^{a, b}	+	+	+	+	+ ^d	276700
Disorders of serine, glycine glycerate metabolism						
Nonketotic hyperglycinemia ^a	+	–	+	+/–	+ ^d	238300
Disorders of amino acid transport						
Lysinuric protein intolerance	–	–	+	+	–	222700
<i>Carbohydrate metabolism</i>						
Disorders of fructose metabolism						
Hereditary fructose intolerance	–	+	–	+	–	229600
Disorders of glycerol metabolism						
Glycerol kinase deficiency	+	+	–	+	–	307030
Disorders of gluconeogenesis						
Fructose-1,6-biphosphatase deficiency	+	+	–	+	–	229700
Phosphoenolpyruvate carboxykinase deficiency	–	+	+	–	–	261650
Glycogen storage disorders						
Glycogen storage disease type Ia (von Gierke disease)	+	+	+	+	–	232200
Glycogen storage disease type Ib	–	–	+	+	–	232220
Glycogen storage disease type II (Pompe disease)	–	–	+	+	+ ^e	232300
<i>Fatty acid and ketone body metabolism</i>						
Disorders of carnitine transport and the carnitine cycle						
Carnitine transporter deficiency ^c	+	+	+	+	+ ^d	212140
Carnitine palmitoyltransferase I deficiency ^c	+	+	+	+	+ ^d	255120
Carnitine acylcarnitine translocase deficiency ^c	+	+	+	+	+ ^d	212138
Carnitine palmitoyltransferase II deficiency ^c	+	+	+	+	+ ^d	255110
Disorders of mitochondrial fatty acid oxidation						
Very long-chain acyl-CoA dehydrogenase deficiency ^{a, b}	+	+	+	+	+ ^d	201475
Mitochondrial trifunctional protein deficiency	+	+	+	+/–	+ ^d	143450
Isolated deficiency of long-chain 3-hydroxylacyl-CoA dehydrogenase ^b	+	+	+	+	+ ^d	143450
Medium-chain acyl-CoA dehydrogenase deficiency ^{a, b}	+	+	+	+	+ ^d	201450
Medium-chain 3-ketoacyl-CoA thiolase deficiency ²	+	–	+	+	–	602199
3-Alpha-hydroxylacyl-CoA dehydrogenase deficiency	+	+	+	+	+ ^d	231530
Multiple acyl-CoA dehydrogenase deficiency ^a	+	+	+	+/–	+ ^d	231680

Table 2 (continued)

Disorder	Neonatal presentation	RS	SID	Treatable	DBS	Phenotype MIM No.
<i>Energy metabolism</i>						
Disorders of pyruvate metabolism						
Pyruvate dehydrogenase complex deficiency	–	+	–	+/–	–	n.s.
Mitochondrial respiratory chain disorders						
Point mutations of mtDNA	+	+	+	–	–	n.s.
Ubiquinone (CoQ10) deficiency (non-LS)	–	+	+	+	–	607426
Complex I deficiency; riboflavin responsive (ACAD9)	–	+	+	–	–	611126
Complex I deficiency	–	–	+	–	–	252010
Complex IV deficiency	+	+	+	–	–	220110
<i>Metabolism of vitamins and (non-protein) cofactors</i>						
Disorders of biotin metabolism						
Biotinidase deficiency	–	–	+	+	+ ^f	253260
Holocarboxylase synthetase deficiency	–	–	+	+	+ ^d	253270

In the SID column, ‘+’ indicates an association with SID in at least 1 of the corresponding references presented in online suppl. table 1. n.s. = Not specified.

¹ Dihydrolipoamide dehydrogenase deficiency (DLD deficiency; MIM No. 246900); ² Medium-chain 3-ketoacyl-CoA thiolase deficiency (MCKAT deficiency; MIM No. 602199); these IEMs were not included in the list of the Society for the Study of Inborn Errors of Metabolism, but were found via the search strategy and were therefore included as IEMs associated with either SID and/or RS.

^a Reported to have caused clinical ascertainment and/or neonatal death before NBS test results were available [6, 7, 10]. ^b Included in the expanded Dutch population NBS Programme since 2007 [25]. ^c Recommended in 2015 for the expansion of the Dutch population NBS Programme [25]. ^d According to McHugh et al. [17]; ^e according to Kishnani et al. [18]; ^f according to Gonzalez et al. [19].

3-hydroxyacyl-CoA dehydrogenase deficiency/mitochondrial trifunctional protein deficiency, medium-chain acyl-CoA dehydrogenase deficiency, maple syrup urine disease and galactosemia (unpubl. data). Patients may also escape early identification due to false-negative NBS results (e.g. patients with carnitine transporter deficiency or very long-chain acyl-CoA dehydrogenase deficiency [21, 22]) or for analytical reasons, which is of concern for patients with carnitine palmitoyltransferase 2 deficiency [23]. These examples stir up the debate on whether the NBS test should be performed earlier in life and/or at 2 different time points.

The general view on ‘the metabolic autopsy’ originated from case studies and small retrospective cohort studies that introduced bias [4]. It is generally recognized that low incidences and aspecific symptoms and signs cause an under-diagnosis of IEMs [9]. Our study strengthens the rationale that, despite a low incidence of individual IEMs, the neonates who died deserved at least a TMS analysis of amino acids and acylcarnitines in a DBS, when feasible. For most of the disorders listed in table 1, the associated recurrence rate for affected families is at least 25%.

Several methodological issues in this study should be mentioned. First, the retrospective design of many of the cohort studies and case studies included might have introduced both a publication bias and a data availability bias as (1) the reports do not always describe detailed patient data and (2) obviously not all SID cases due to IEMs get reported in the literature. Second, there are many factors including aspecific symptoms that lead to under-diagnosis of IEMs in neonates [9]. Third, despite our extensive and detailed search strategy, we cannot exclude the possibility that a few references were missed. This was emphasized by the fact that, after including the full-text articles in the first round (n = 91), new references still emerged via the reference lists of excluded and included full-text articles. In order to optimize the search strategy, we conducted a second (n = 44) and third (n = 1) screening round. Fourth, in the medical literature, the definition of SID is not always consistently applied with regard to age range and clinical symptoms and signs. In an attempt to overcome this, we added the term ‘sudden unexpected death of infant’ to our search strategy. Last, some included IEMs exemplify only one protein deficiency in a large metabolic pathway involving many enzymes and transporters that could potentially create a similar clinical pic-

ture. Therefore, we believe, based on our systematic review, that the IEMs included in table 1 should be considered as the minimal number of IEMs associated with SID and/or RS. Despite expanding NBS programmes, clinical awareness needs to remain high amongst neonatologists and paediatricians because many IEMs have not yet been implemented in NBS programmes. It is possible that early recognition of clinical presentations and subsequent diagnostic testing could prevent fatal outcomes [24].

In summary, our systematic review identified the IEMs that are associated with RS and SID, a significant proportion of which are treatable disorders. In our opinion, the analysis of amino acids and acylcarnitines in blood/plasma/DBS and urine should be part of post-mortem diagnostic protocol, next to the isolation of DNA and, prefer-

entially, material for functional tests such as the analysis of cultured skin fibroblasts. The combination of metabolite screening and DNA-sequencing techniques would harbor the best of both methods, i.e. fast identification and a high diagnostic yield.

Acknowledgements

The authors would like to thank Mirell H.G. Papenhuijzen for her assistance in performing the search.

Disclosure Statement

The authors have nothing to declare.

References

- Boles RG, Buck EA, Blitzer MG, Platt MS, Cowan TM, Martin SK, Yoon H, Madsen JA, Reyes-Mugica M, Rinaldo P: Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. *J Pediatr* 1998;132:924–933.
- Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, Naylor EW: Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. *Clin Chem* 2001;47:1166–1182.
- Green A, Preece MA, Hardy D: More on the metabolic autopsy. *Clin Chem* 2002;48:964–965.
- Ernst LM, Sondheimer N, Deardorff MA, Bennett MJ, Pawel BR: The value of the metabolic autopsy in the pediatric hospital setting. *J Pediatr* 2006;148:779–783.
- Millington DS, Kodo N, Norwood DL, Roe CR: Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. *J Inher Metab Dis* 1990;13:321–324.
- Wilcken B, Wiley V, Hammond J, Carpenter K: Screening newborns for inborn errors of metabolism by tandem mass spectrometry. *N Engl J Med* 2003;348:2304–2312.
- Frazier DM, Millington DS, McCandless SE, Koeberl DD, Weavil SD, Chaing SH, Muenzer J: The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. *J Inher Metab Dis* 2006;29:76–85.
- Yusuf K, Jirapradittha J, Amin HJ, Yu W, Hasan SU: Neonatal ventricular tachyarrhythmias in medium chain acyl-CoA dehydrogenase deficiency. *Neonatology* 2010;98:260–264.
- Derks TG: Sweet and sour aspects of medium-chain acyl CoA dehydrogenase deficiency. Commentary on K. Yusuf et al.: Neonatal ventricular tachyarrhythmias in medium chain acyl-CoA dehydrogenase deficiency (Neonatology 2010;98:260–264). *Neonatology* 2010;98:265–267.
- Lindner M, Gramer G, Haeghe G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF: Efficacy and outcome of expanded newborn screening for metabolic diseases – report of 10 years from South-West Germany. *Orphanet J Rare Dis* 2011;6:44–1172.
- Rijpstra A, Schonbeck Y, Verkerk PH: Evaluatie van de Neonatale Hieprikscreening bij Kinderen Geboren in 2013. Leiden, TNO, 2015.
- Centrum voor Bevolkingsonderzoek: Draaiboek Neonatale Hieprikscreening. Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2015.
- Reye RD, Morgan G, Baral J: Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood. *Lancet* 1963;2:749–752.
- Orlowski JP: Whatever happened to Reye's syndrome? Did it ever really exist? *Crit Care Med* 1999;27:1582–1587.
- Society for the Study of Inborn Errors of Metabolism: Classification of Inborn Errors of Metabolism 2011.
- Saudubray JM, van den Berghe G, Walter JH: *Inborn Metabolic Diseases: Diagnosis and Treatment*, ed 5 (revised). Heidelberg, Springer, 2011.
- McHugh D, Cameron CA, Abdenur JE, et al: Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. *Genet Med* 2011;13:230–254.
- Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O'Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tiffit CJ, Watson MS; ACMG Work Group on Management of Pompe Disease: Pompe disease diagnosis and management guideline. *Genet Med* 2006;8:267–288.
- Gonzalez EC, Marrero N, Frometa A, Herrera D, Castells E, Perez PL: Qualitative colorimetric ultramicroassay for the detection of biotinidase deficiency in newborns. *Clin Chim Acta* 2006;369:35–39.
- Marsden D, Larson C, Levy HL: Newborn screening for metabolic disorders. *J Pediatr* 2006;148:577–584.
- Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Duno M, Skogstrand K, Olsen RK, Jensen UG, Cohen A, Larsen N, Saugmann-Jensen P, Gregersen N, Brandt NJ, Christensen E, Skovby F, Norgaard-Pedersen B: Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland – experience and development of a routine program for expanded newborn screening. *Mol Genet Metab* 2012;107:281–293.
- Ficicioglu C, Coughlin CR 2nd, Bennett MJ, Yudkoff M: Very long-chain acyl-CoA dehydrogenase deficiency in a patient with normal newborn screening by tandem mass spectrometry. *J Pediatr* 2010;156:492–494.
- de Sain-van der Velden MG, Diekman EF, Jans JJ, van der Ham M, Prinsen BH, Visser G, Verhoeven-Duif NM: Differences between acylcarnitine profiles in plasma and bloodspots. *Mol Genet Metab* 2013;110:116–121.
- Derks TG, Jakobs H, Gerding A, Niezen-Koning KE, Reijngoud DJ, Smit GP: Deficiency of the fatty-acid oxidising enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in an adult, detected during a neonatal screening programme. *Ned Tijdschr Geneesk* 2004;148:2185–2190.
- Health Council of the Netherlands: Neonatal screening: new recommendations 2015; 2015/08.